Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $113.90 | Total: $569.50 |
| 1 | 10 | $96.48 | Total: $964.80 |
| 1 | 25 | $81.74 | Total: $2,043.50 |
| 1 | 50 | $69.68 | Total: $3,484.00 |
| 1 | 100 | $60.30 | Total: $6,030.00 |
Overview
TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.
Chemical Properties
| Molecular Formula | C21H21FN6O3 |
| Molecular Weight | 424.43 |
| CAS Numbers | 2359650-19-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | FC=1C=C2CN3C=4C(=CN5C(N4)=C(C=N5)C(=O)NC[C@@H](C)OC2=NC1)O[C@]6([C@@]3(CCC6)[H])[H] |
Storage and Handling
0C Short Term, -20C Long Term
References
Repetto M, et al. The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046. Invest New Drugs. 2022 May 25.